Literature DB >> 10963205

Blood stem-cell transplantation for chronic active Epstein-Barr virus with lymphoproliferation.

T Okamura, Y Hatsukawa, H Arai, M Inoue, K Kawa.   

Abstract

A boy with chronic active Epstein-Barr virus infection (EBV) developed bilateral exophthalmos by infiltrating EBV-infected natural-killer cells during combined chemotherapy. This unusual presentation resolved completely after allogeneic bone-marrow transplantation, and EBV-infected peripheral T and natural-killer cells were also eradicated.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10963205     DOI： 10.1016/S0140-6736(00)02488-0

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  20 in total

Review 1.  How we treat chronic active Epstein-Barr virus infection.

Authors:  Akihisa Sawada; Masami Inoue; Keisei Kawa
Journal:  Int J Hematol       Date:  2017-02-16       Impact factor: 2.490

2.  Preferential expansion of Vgamma9-JgammaP/Vdelta2-Jdelta3 gammadelta T cells in nasal T-cell lymphoma and chronic active Epstein-Barr virus infection.

Authors:  Michiko K Oyoshi; Hiroshi Nagata; Nobuhiro Kimura; Yu Zhang; Ayako Demachi; Toshiro Hara; Hirokazu Kanegane; Yoshinobu Matsuo; Tomohiro Yamaguchi; Tomohiro Morio; Atsuyoshi Hirano; Norio Shimizu; Kohtaro Yamamoto
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

3.  Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States.

Authors:  Jeffrey I Cohen; Elaine S Jaffe; Janet K Dale; Stefania Pittaluga; Helen E Heslop; Cliona M Rooney; Stephen Gottschalk; Catherine M Bollard; V Koneti Rao; Adriana Marques; Peter D Burbelo; Siu-Ping Turk; Rachael Fulton; Alan S Wayne; Richard F Little; Mitchell S Cairo; Nader K El-Mallawany; Daniel Fowler; Claude Sportes; Michael R Bishop; Wyndham Wilson; Stephen E Straus
Journal:  Blood       Date:  2011-03-31       Impact factor: 22.113

4.  Biclonal expansion of T cells infected with monoclonal Epstein-Barr virus (EBV) in a patient with chronic, active EBV infection.

Authors:  S Toyabe; W Harada; M Uchiyama
Journal:  Clin Exp Immunol       Date:  2003-10       Impact factor: 4.330

5.  Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8-9 September 2008.

Authors:  J I Cohen; H Kimura; S Nakamura; Y-H Ko; E S Jaffe
Journal:  Ann Oncol       Date:  2009-06-10       Impact factor: 32.976

6.  Cytotoxic chemotherapy successfully induces durable complete remission in 2 patients with mosquito allergy resulting from Epstein-Barr virus-associated T-/natural killer cell lymphoproliferative disease.

Authors:  M Koyama; Y Takeshita; A Sakata; A Sawada; M Yasui; T Okamura; M Inoue; K Kawa
Journal:  Int J Hematol       Date:  2005-12       Impact factor: 2.490

Review 7.  Extranodal natural killer/T-cell lymphoma: current concepts in biology and treatment.

Authors:  Holbrook Kohrt; Ranjana Advani
Journal:  Leuk Lymphoma       Date:  2009-11

8.  Clinical effects of infusing anti-Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes into patients with severe chronic active EBV infection.

Authors:  Masao Hagihara; Takahide Tsuchiya; Osamu Hyodo; Yoko Ueda; Kei Tazume; Aya Masui; Ayako Kanemura; Fumiaki Yoshiba; Shinji Takashimizu; Shohei Matzusaki; Shunichi Kato; Tomomitsu Hotta
Journal:  Int J Hematol       Date:  2003-07       Impact factor: 2.490

Review 9.  Diagnosis and treatment of Epstein-Barr virus-associated natural killer cell lymphoproliferative disease.

Authors:  Keisei Kawa
Journal:  Int J Hematol       Date:  2003-07       Impact factor: 2.490

10.  Optimal treatment for chronic active Epstein-Barr virus disease.

Authors:  Jeffrey I Cohen
Journal:  Pediatr Transplant       Date:  2009-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.